~~<i id='6E1A2CB735'><strike id='6E1A2CB735'><tt id='6E1A2CB735'><pre id='6E1A2CB735'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

fashion

author：knowledge 2025-10-02 12:32:00 - browse：748

Biotech and life sciences investors continue to draw in new funds even as the biotech stock indexes reach new lows.

On Wednesday, VC firm Bioluminescence Ventures launched with $477 million to invest in biotech startups. The firm was founded by Kouki Harasaki, who was previously a partner at M12, Microsoft’s corporate venture group, and Andreessen Horowitz. He also has a track record at pharmaceutical companies like Novartis and Baxalta.

Bioluminescence joined at least four other firms — OrbiMed, Sofinnova Partners, Abingworth, and Revelation Partners — in announcing new pools of capital in the last two weeks. Together, they have raised $5.94 billion.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Curing rare childhood diseases will falter unless Congress steps up

focus

explore

Wikipedia

leisure time

hotspot

focus

RobertMontgomeryofNewYorkUniversityspeaksasMeganSykesofColumbiaUniversityandInsooHyunofHarvardMedica

WSS

Eli Lilly’s Mounjaro succeeds in second weight

How faith leaders like me can help address America's obesity epidemic

Moderna says combo Covid

Cigna wins case to block Amy Bricker's move to CVS

'Essentially witchcraft:' A former naturopath takes on the field

A public health expert passes on football's full body collisions for youths

entertainment

fashion

focus

Wildfire smoke exposes gaps in outdoor worker protections

Over 1,300 arrested in France in 4th night of protests over fatal police shooting of teen Nahel M.

Medical records are filled with copy

Timeline: Key moments in fight for gay rights

Cancer drug shortages should be causing more outrage

Can medical device makers keep up in the race to treat obesity?

Trump demands the U.S. pay no more for drugs than other countries … again

NIH tests clinical research in primary care with $30 million program

Novavax promises a turnaround & Lilly roils the obesity market

Deposition: Sackler embraced plan to conceal OxyContin’s strength

explore

How to fix the rural physician shortage in the U.S.

Over 1,300 arrested in France in 4th night of protests over fatal police shooting of teen Nahel M.

Deposition: Sackler embraced plan to conceal OxyContin’s strength

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

Pharma companies must ensure equitable access to obesity drugs

Novo pauses ads for weight loss drug Wegovy amid demand

Wikipedia

leisure time

hotspot

focus